000 01555 a2200373 4500
005 20250516101942.0
264 0 _c20130225
008 201302s 0 0 chi d
022 _a0253-3766
024 7 _a10.3760/cma.j.issn.0253-3766.2012.02.018
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aXu, Jian-Ming
245 0 0 _a[More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].
_h[electronic resource]
260 _bZhonghua zhong liu za zhi [Chinese journal of oncology]
_cFeb 2012
300 _a158-60 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAntibodies, Monoclonal, Humanized
_xtherapeutic use
650 0 4 _aAntineoplastic Agents
_xtherapeutic use
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xtherapeutic use
650 0 4 _aBevacizumab
650 0 4 _aGastrointestinal Neoplasms
_xclassification
650 0 4 _aHumans
650 0 4 _aIndoles
_xtherapeutic use
650 0 4 _aNeuroendocrine Tumors
_xclassification
650 0 4 _aOctreotide
_xtherapeutic use
650 0 4 _aPancreatic Neoplasms
_xclassification
650 0 4 _aPeptides, Cyclic
_xtherapeutic use
650 0 4 _aPyrroles
_xtherapeutic use
650 0 4 _aSirolimus
_xanalogs & derivatives
650 0 4 _aSomatostatin
_xanalogs & derivatives
650 0 4 _aSunitinib
773 0 _tZhonghua zhong liu za zhi [Chinese journal of oncology]
_gvol. 34
_gno. 2
_gp. 158-60
856 4 0 _uhttps://doi.org/10.3760/cma.j.issn.0253-3766.2012.02.018
_zAvailable from publisher's website
999 _c21932761
_d21932761